摘要
1978年,Cohen等研究发现腺苷脱氨酶(ADA)生成缺陷可以导致三磷酸脱氧腺苷(dATP)在细胞内有毒蓄积并进而引起特异性的淋巴细胞死亡。
出处
《中国处方药》
2013年第3期32-35,共4页
Journal of China Prescription Drug
参考文献16
-
1Cohen A,Hirschhorn R,Horowitz SD,et al.Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.Proc Natl Acad Sci USA,1978,75(1):472-476.
-
2Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.Proc Natl Acad Sci USA,1980,77(11):6865-6869.
-
3Sigal DS,Miller HJ, Schram ED,et al.Beyond hairy cell: the activity of cladribine in other hematologic malignancies.Blood,2010,11616):2884 -2896.
-
4Torrey ML, Sigal DS, Saven A.Development of cladribine at Scripps for hairy cell leukemia and current results.Leuk Lymphoma,2011,52(2):29-33.
-
5Robak T, Jamroziak K,Gora-Tybor J,et al.Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a pmspective,ra ndomized,multicenter trisl.Blood,2007,109(9):3672-3675.
-
6Tallman MS,Zakarija A.Hairy cell leukemia: survival and relapse.Long-term follow-up of purine anaiog-based therapy and approach for relapsed disease. Transfus Apher Sci,2005,32(1): 99-103.
-
7Goodman GR,Burian C,Koziol JA,et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.J Clin Oncol,2003,21(5): 891-896.
-
8Seymour JF, Kurzrock R,Freireich EJ,et al.2- chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.Blood, 1994,83(10):2906- 2911.
-
9Tadmor T.Purine analog toxicity in patients with hairy cell leukemia.Leuk Lymphoma,2011,52 (Suppl 2):38-42.
-
10Else M,Dearden CE,Matutes E,et ai.Long-term follow-up of 233 patients with hairy cell leukaemia,treated initially with pentostatin or cladribine,at a median of 16 years from diagnosis.Br J Haematol, 2009,145(6):733-740.
同被引文献47
-
1Estey E,Dohner H. Acute myeloid leukemia[-J2. Lan- cet, 2006,368 : 1894 - 907.
-
2Wei G,Ni W,Chiao JW,et al. A recta-analysis of CAG (cytarabine, aclarubicin, C,-CSF) regimen for the treat- ment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome[J]. J Hematol Oncol, 2011, 14:46-58.
-
3Miyawaki S,Kawai Y,Takeshita A, et al. Phase 1 trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia= study of the Japan Adult I.eukemia Study Group (IALSG) [J]. Int J Hematol,2007,86:343-347.
-
4Carella MA,Cascavilla N,Greco MM,et al. Treatment of " poor risk" acute myeloid leukemia with fludara- bine, eytarabine and G CSF (flag regimen): a single centre study T- J 1. I.euk Lymphoma, 2001, 40=295-303.
-
5Robak T. Purine nueleoside analogues in the treatment of myeloid leukemias[J]. Leuk Lymphoma, 2003,44: 391-409.
-
6Robak T,Wierzbowska A. Cladribine in the treatment of acute rnyeloid leukemia [J]. Leuk Res, 2014, 38: 425-427.
-
7Robak P, Robak T. Older and new purine nueleoside analogs for patients with acute leukemias[J]. CancerTreat Rev,2013,39: 851- 861.
-
8Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias[J]. Leuk Lymphoma, 2003,44 : 391-409.
-
9Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mi- toxantrone,and G-CSF (CLAG-M) is a highly effec- tive salvage regimen in patients with refractory and re- lapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group[J]. Eur J Haematol, 2008,80 : 115 - 126.
-
10曹宁川,杨向红.肿瘤细胞对体外诱导人内皮细胞血管形成的影响及VEGF的作用[J].中国医科大学学报,2008,37(3):405-407. 被引量:6
引证文献10
-
1甘茂周,尹晓东.CLAG方案治疗复发/难治性急性髓细胞白血病疗效观察[J].临床血液学杂志,2015,28(3):419-422. 被引量:4
-
2李琼琼,王瑞仓,李杰,袁军,杨洁,李燕,王素云,郝洪岭.毛细胞白血病合并甲状腺癌一例报道及文献复习[J].中国综合临床,2017,33(1):73-74.
-
3钱娟,施文瑜,张亚平,杨力,刘红.改良CLAG方案治疗复发难治性急性髓系白血病的效果观察[J].交通医学,2017,31(6):527-529. 被引量:3
-
4王小华,陈丽璇,张红,韩娜,段锋祺,周兆,吕林林,肖扬,刘革修.克拉屈滨对人脐静脉内皮细胞的毒性作用及机制[J].中国动脉硬化杂志,2018,26(5):451-456.
-
5王宇阳,李君惠,胡涛,常会波,张朝霞,张蕾,冯顺乔,刘嵘,师晓东,宋福英,张淑一.克拉屈滨联合阿糖胞苷治疗高危/难治性儿童急性髓细胞白血病及侵袭性NK/T细胞淋巴瘤[J].中华妇幼临床医学杂志(电子版),2018,14(4):391-397. 被引量:1
-
6张燕,熊杰,王季石.急性髓系白血病骨髓移植术后乳腺复发一例报告[J].天津医药,2017,45(5):536-538. 被引量:2
-
7陈丽璇,张红,王小华,段锋祺,周兆,刘革修.克拉屈滨对人脐静脉内皮细胞活力和代谢的影响[J].中国病理生理杂志,2018,34(4):605-610.
-
8王亚文,薛宏伟.RC方案治疗复发/难治套细胞淋巴瘤的临床效果[J].青岛大学学报(医学版),2019,55(4):478-480. 被引量:1
-
9曹红刚,吴涛,薛锋,汉英,王存邦,白海.CLAG方案治疗ETO阴性合并CEBPA突变WT1阳性急性髓系白血病M2一例并文献复习[J].白血病.淋巴瘤,2019,28(9):554-556.
-
10林玉奇,陈香丽,臧玉柱,张磊,张文荟,孙恺,王亚彩.双表达弥漫大B细胞淋巴瘤自体造血干细胞移植复发后嵌合抗原受体T细胞免疫治疗持续缓解一例并文献复习[J].白血病.淋巴瘤,2020,29(5):288-290. 被引量:1
二级引证文献12
-
1周海侠,胡晓慧,吴德沛.克拉屈滨联合化疗对于复发/难治急性髓细胞白血病的疗效观察[J].中国血液流变学杂志,2015,0(3):279-281. 被引量:3
-
2卜声镝,陈江明,蔡宁,李金燕,黄兰.复发难治性急性髓系白血病的治疗现状及进展[J].中外医学研究,2018,16(12):186-188. 被引量:6
-
3张燕,熊杰,王季石.急性髓系白血病骨髓移植术后乳腺复发一例报告[J].天津医药,2017,45(5):536-538. 被引量:2
-
4杨丽喆,张燕,赵鹏,熊杰,黄懿,王季石.急性白血病异基因造血干细胞移植术后单纯髓外复发的临床观察[J].江西医药,2019,54(2):114-116. 被引量:2
-
5曹红刚,吴涛,薛锋,汉英,王存邦,白海.CLAG方案治疗ETO阴性合并CEBPA突变WT1阳性急性髓系白血病M2一例并文献复习[J].白血病.淋巴瘤,2019,28(9):554-556.
-
6张国华.复发难治性急性髓系白血病临床治疗的疗效观察[J].临床医药文献电子杂志,2019,6(74):78-78. 被引量:3
-
7王亚彩,陈香丽,臧玉柱,陈玉清,张文荟,林玉奇.CLAG-M在挽救治疗复发难治性急性髓系白血病中的临床意义[J].医药论坛杂志,2020,41(2):1-6. 被引量:1
-
8杨翠云,张晓莉,李毓,罗学群,黄礼彬.克拉屈滨联合化疗治疗儿童AML 1例[J].中国小儿血液与肿瘤杂志,2021,26(3):177-178.
-
9伍春兰,李书兵,薛恒.乳腺白血病浸润超声表现1例[J].临床超声医学杂志,2021,23(7):520-520.
-
10寇明坤,吴涛,徐娜娜,梁顺,玉白海.套细胞淋巴瘤治疗进展[J].白血病.淋巴瘤,2021,30(9):572-576. 被引量:1
-
1徐大兴,李森,李艳杰,陈琳琳,吴浩.病毒性脑膜炎患者脑脊液中乳酸脱氢酶、腺苷脱氨酶及肿瘤坏死因子-α的水平变化及临床意义[J].实用临床医药杂志,2016,20(24):26-28. 被引量:9
-
2杨顺,钱建新,张萍,肖燕.脑脊液中免疫球蛋白及腺苷脱氨酶测定对三种脑膜炎的诊断价值[J].河南实用神经疾病杂志,2003,6(3):11-12.
-
3曾可斌,王学峰,沈鼎烈.多发性硬化的治疗[J].国外医学(内科学分册),2001,28(11):488-491. 被引量:1
-
4克拉屈滨可治疗复发-缓解型多发性硬化[J].中华医学信息导报,2009,24(10):9-9.
-
5陈海丝,杨欣,黄锦海.多发性硬化症新型药物克拉屈滨的研究进展[J].医学综述,2014,20(23):4343-4346. 被引量:1
-
6陈龙法.神经元特异性烯醇化酶、基质金属蛋白酶-9、腺苷脱氨酶及肿瘤坏死因子-α在结核性脑膜炎诊断中的应用[J].中国医师进修杂志,2012,35(33):12-15. 被引量:3
-
7韩磊.口服克拉屈滨治疗复发性多发性硬化CLARITY研究结果公布[J].山东医药,2010,50(4):25-25.
-
8李美珠,梁指荣,郑雪莲.肝硬化患者超敏-C反应蛋白、腺苷脱氨酶检测结果分析[J].国际检验医学杂志,2011,32(19):2267-2268. 被引量:5
-
9周官恩,安中平.多发性硬化口服药物研究新进展[J].中国现代神经疾病杂志,2012,12(2):147-151. 被引量:3
-
10治疗多发性硬化症新药克拉屈滨在澳大利亚上市[J].世界临床药物,2011,32(3):191-191.